Dompé Farmaceutici S.p.A
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Dompé Farmaceutici S.p.A sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).
Dompé Farmaceutici S.p.A: 27 sponsored US clinical trials, 4 recruiting.
Dompé Farmaceutici S.p.A sponsors 27 registered US clinical trials on ClinicalTrials.gov, 4 of them currently recruiting, and 18 completed. 9 of these trials are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Dry Eye Disease, with 2 trials.
Top-decile sponsor footprint
Dompé Farmaceutici S.p.A ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 23 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
27 total, page 1 of 1
Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
NCT07453888
An Efficacy and Safety Study of Cenegermin Ophthalmic Solution Compared With Vehicle in the Treatment of PCED
NCT07519902
An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease
NCT07503886
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
NCT07395232
Study to Evaluate Corneal Neurosensory Abnormalities in Patients With Sjögren's Dry Eye
NCT06411132
A Safety and Efficacy Study of 2 Dosing Regimens of Recombinant Human Nerve Growth Factor (rhNGF) Eye Drop Solution Compared With Vehicle in Patients With Dry Eye Disease.
NCT06244316
DEFENDO Long Term Follow-up Study in Stage 1 NK Patients
NCT05552261
Add-on Reparixin in Adult Patients With ARDS
NCT05496868
Reparixin add-on Therapy to Standard Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia
NCT05254990
Study to Evaluate Safety and Efficacy of Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease
NCT05136170
Safety and Efficacy Study on Cenegermin (Oxervate®) vs Vehicle in Severe Sjogren's Dry Eye Disease (PROTEGO-1 Study)
NCT05133180
Study on Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients With Severe COVID-19 Pneumonia.
NCT04878055
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
NCT04628481
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
NCT04899271
Study to Evaluate OXERVATE® in Patients With Stage 1 Neurotrophic Keratitis
NCT04485546
A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye
NCT03982368
Study to Evaluate Safety, Tolerability & PK of rhNGF in Healthy Volunteers
NCT03836859
An 8-week Study to Evaluate Safety and Efficacy of NGF Eye Drops Solution Versus Vehicle in Patients With Dry Eye
NCT03019627
Study to Evaluate Safety and Efficacy of rhNGF Eye Drops Solution Versus Vehicle in Patients With Glaucoma
NCT02855450
A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer
NCT02370238
Evaluation of Efficacy of 20 µg/ml rhNGF New Formulation (With Anti-oxidant) in Patients With Stage 2 and 3 NK
NCT02227147
Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
NCT01967888
Pilot Study to Evaluate Safety & Biological Effects of Orally Administered Reparixin in Early Breast Cancer
NCT01861054
Study to Assess Efficacy & Safety of Reparixin in Pancreatic Islet Transplantation
NCT01817959
Pilot Study to Evaluate Reparixin With Weekly Paclitaxel in Patients With HER 2 Negative Metastatic Breast Cancer (MBC)
NCT02001974
Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation
NCT00248040
Repertaxin in Prevention of Primary Graft Dysfunction After Lung Transplantation
NCT00224406
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 13 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Dompé Farmaceutici S.p.A pipeline
4 recruiting of 27 indexed (15% open); 18 completed (67%).
Phase mix: 9 late (III/IV) vs 16 early (I/II) (early-phase heavy).
Top condition: Dry Eye Disease (2 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Dompé Farmaceutici S.p.A: open-pipeline peers nationwide
Peers matched on 27 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
Dompé Farmaceutici S.p.A sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 27 trials (± recruiting share)
- Akron Children's Hospital · 27 trials · 7% recruiting
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 27 trials · 0% recruiting
- AVEO Pharmaceuticals · 27 trials · 7% recruiting
- Florida Atlantic University · 27 trials · 19% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Vanderbilt-Ingram Cancer Center · 15% recruiting · 189 trials
- University of Rochester · 15% recruiting · 636 trials
- Loma Linda University · 15% recruiting · 237 trials
- University of Washington · 15% recruiting · 1,048 trials
Related
What to do with this Dompé Farmaceutici S.p.A page
27 registered trials is a research-attention snapshot, not an endorsement of Dompé Farmaceutici S.p.A or any single study.
- 4 of Dompé Farmaceutici S.p.A's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Dry Eye Disease is the condition Dompé Farmaceutici S.p.A studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Dry Eye Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Dompé Farmaceutici S.p.A pipeline card: 27 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.